Cabaletta Bio, Inc. $CABA Position Raised by JPMorgan Chase & Co.

Key Points

• JPMorgan boosted its stake in Cabaletta Bio by 565.4% in Q3, acquiring an additional 456,853 shares to hold 537,649 shares (about 0.56% of the company) valued at roughly $1.26 million.
• Other institutions (Invesco, Comerica, Marshall Wace, AQR, XTX) have also recently increased or initiated positions, and company insiders bought 127,668 shares in the last three months, bringing insider ownership to 11.25%.
• Cabaletta trades around $3.17 with a market cap of ~$353 million and a 52-week range of $1.04–$3.78, yet analysts show bullish upside with an average target of about $17 and a "Moderate Buy" consensus.

JPMorgan Chase & Co. raised its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 565.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 537,649 shares of the company's stock after buying an additional 456,853 shares during the period. JPMorgan Chase & Co. owned approximately 0.56% of Cabaletta Bio worth $1,258,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of CABA. Invesco Ltd. raised its holdings in Cabaletta Bio by 357.1% during the 1st quarter. Invesco Ltd. now owns 61,675 shares of the company's stock worth $85,000 after buying an additional 48,181 shares during the period. Comerica Bank raised its holdings in Cabaletta Bio by 2,292.1% during the 1st quarter. Comerica Bank now owns 41,599 shares of the company's stock worth $58,000 after buying an additional 39,860 shares during the period. AQR Capital Management LLC acquired a new stake in Cabaletta Bio during the 1st quarter worth about $102,000. XTX Topco Ltd acquired a new stake in Cabaletta Bio during the 2nd quarter valued at $148,000. Finally, Marshall Wace LLP raised its stake in Cabaletta Bio by 470.7% during the 2nd quarter. Marshall Wace LLP now owns 190,957 shares of the company's stock valued at $290,000 after purchasing an additional 157,497 shares during the period.

Cabaletta Bio Price Performance

Cabaletta Bio stock opened at $3.17 on Friday. The company has a market capitalization of $352.88 million, a price-to-earnings ratio of -1.39 and a beta of 3.30. Cabaletta Bio, Inc. has a one year low of $1.04 and a one year high of $3.78. The company's fifty day moving average price is $2.94 and its two-hundred day moving average price is $2.62.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. As a group, sell-side analysts anticipate that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CABA. Weiss Ratings reissued a "sell (d-)" rating on shares of Cabaletta Bio in a research note on Wednesday, January 21st. Morgan Stanley cut their target price on shares of Cabaletta Bio from $14.00 to $13.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 24th. Wall Street Zen raised shares of Cabaletta Bio from a "strong sell" rating to a "hold" rating in a research note on Sunday, March 29th. Finally, Guggenheim boosted their target price on shares of Cabaletta Bio from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $17.00.

Insider Buying and Selling at Cabaletta Bio

In other Cabaletta Bio news, Director Mark Simon purchased 11,061 shares of the firm's stock in a transaction on Wednesday, January 21st. The shares were purchased at an average price of $2.28 per share, for a total transaction of $25,219.08. Following the completion of the purchase, the director directly owned 147,205 shares of the company's stock, valued at approximately $335,627.40. This represents a 8.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Shawn Tomasello purchased 22,725 shares of the firm's stock in a transaction on Wednesday, January 21st. The shares were acquired at an average price of $2.21 per share, for a total transaction of $50,222.25. Following the purchase, the director directly owned 22,725 shares of the company's stock, valued at approximately $50,222.25. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 127,668 shares of company stock worth $286,211 over the last three months. 11.25% of the stock is currently owned by corporate insiders.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.